Delivery Order SPE2DB22D3501-SPE2DB25FWR08
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $10,519.62 to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Lynparza 100 mg tablets (120-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 30, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $10,499.34 to AmerisourceBergen Drug Corp for 60 tablets of LYNPARZA 150 mg, a pharmaceutical product for oncology treatment. The contract, awarded on August 19, 2025, with an ultimate completion date of September 10, 2025, carries firm fixed pricing and represents a non-set-aside competitive award. Performance will be executed at the contractor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Lynparza 150 mg tablets (120-count units) with a firm fixed price ceiling value of $21,135.20 and ultimate completion date of September 10, 2025. This delivery order represents a non-competitive award and is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order valued at $10,567.60 to AmerisourceBergen Drug Corp for the supply of Lynparza 150 mg tablets (120-count units). The contract was awarded on August 12, 2025, with an ultimate completion date of September 3, 2025, and is structured as a firm fixed-price delivery order with no set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $10,519.62 to AmerisourceBergen Drug Corp for 120 tablets of Lynparza 100 mg on August 20, 2025, with an ultimate completion date of September 11, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child order, this delivery falls under a larger contract...
- The Defense Logistics Agency awarded a delivery order valued at $31,702.80 to AmerisourceBergen Drug Corp for the supply of Lynparza 150 mg tablets (120-count units) on September 16, 2025, with an ultimate completion date of October 7, 2025. This firm fixed-price delivery order carries no set-aside designation and represents a competitive award under the company's broader pharmaceutical supply relationships with the federal government. The place of performance is AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $10,543.70 to AmerisourceBergen Drug Corp for 60 tablets of Lynparza 100 mg, a prescription oncology medication. This firm fixed-price delivery order was competitively awarded with no set-aside designation and carries an ultimate completion date of August 25, 2025. The contract was executed on August 4, 2025, with performance to be completed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Lynparza 150 mg tablets (120-count units) valued at $10,567.60, with completion expected by July 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of LYNPARZA 150 mg tablets in quantities of 60 units. This contract, valued at $10,499.34, represents a firm fixed-price delivery order with an ultimate completion date of September 22, 2025. The award was made through open competition with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, fulfills this order through its...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $31,702.80 on June 16, 2025, for the supply of Lynparza 150 mg tablets (120-count units). This firm fixed-price, competitively awarded contract has a completion date of July 9, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified pharmaceutical distributors. This...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FWR08Delivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,543.70 for 60 tablets of Lynparza 100 mg on July 30, 2025, with an ultimate completion date of August 20, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and is being fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location. The contract represents a continuation of pharmaceutical supply services under AmerisourceBergen's broader federal contract portfolio with DLA. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The parent IDC, designated SPE2DX, serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs worldwide. Lynparza, an oncology medication, aligns with AmerisourceBergen's established role as a critical vendor for federal medical procurement serving the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.5k | 7/30/25 |